Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human α-thrombin

Protein Science

Volumn 5, Issue 6, 1996, Pages 1174-1183

  Fethiere J ^b   Tsuda, Yuko ^b   Coulombe, René ^b   Konishi, Yasuo ^b   Cygler, Miroslaw ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b NONE

Author keywords

arginine methyl esters; bifunctional inhibitors; crystal structure; thrombin

Indexed keywords

ARGININE METHYL ESTER; FIBRINOGEN; HIRUDIN; HYDROGEN; THROMBIN; THROMBIN INHIBITOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; HYDROGEN BOND; PRIORITY JOURNAL; X RAY DIFFRACTION;

EID: 0029896898     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560050620     Document Type: Article

References (43)

1. Angelli G, Pascucci C, Cosmi B, Nenci GG. 1991. Effect of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits. Thromb Haemostasis 66:592-597.
2. Badimon L, Merino A, Badimon J, Chesebro JH, Fuster V. 1991. Hirudin and other thrombin inhibitors: Experimental research and potential clinical application. Trends Cardiov Med 1:261-267.
3. Banner DW, Hadvàry P. 1991. Cristallographic analysis at 3.0 Å resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem 266:20085-20093.
4. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. 1989. The refined 1.9 Å crystal structure of human α-thrombin: Interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 5:3467-3475.
5. Bode W, Turk D, Karshikov A. 1992. Electrostatic interactions in the association of proteins: An analysis of the thrombin-hirudin complex. Protein Sci 1:426-471.
6. Brandstetter H, Turk D, Hoeffken HW, Grosse D, Sturzebecher J, Martin PD, Edwards BFP, Bode W. 1992. Refined 2.3 Å X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. J Mol Biol 226:1085-1099.
7. Brunger AT. 1992. X-PLOR, version 3.1. A system for X-ray crystallography and NMR. New Haven, Connecticut: Yale University Press.
8. Cairns JA, Fuster V, Kennedy JW. 1992. Coronary thrombolysis, CHEST 102(Suppl):482S-507S.
9. Coller BS. 1990. Seminars on Medicine of the Beth Israel Hospital, Boston. New Engl J Med 522:33-42.
10. DiMaio J, Ni F, Gibbs B, Konishi Y. 1991 A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond. FEBS Lett 252:47-52.
11. DiMaio J, Gibbs B, Konishi Y, Lefebvre J, Munn D 1992. Synthesis of a homologous series of ketomethylene arginyl pseudopeptides and application to low molecular weight hirudin-like thrombin inhibitors. J Med Chem 35:3331-3341.
12. Fenton JW II. 1981. Thrombin specificity. Ann NY Acad Sci 370:468-495.
13. Grutter GM, Priestle PJ, Rahuel J, Grossenbacher H, Bode W, Hofsteenge J, Stone SR. 1990. Crystal structure of the thrombin-hirudin complex: A novel mode of serine protease inhibition. EMBO J 9:2361-2365.
14. Hauptmann J, Markwardt F. 1992. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Sem Thromb Hemost 18:200-217.
15. Janin J, Wodak S, Levitt M, Maigret B. 1978. Conformation of amino acid side-chains in proteins. J Mol Biol 125:357-386.
16. Jones TA, Zou JY, Cowan SW. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47:110-119.
17. Kikumoto R, Tamao Y, Ohkubo K, Tezuka T, Tonomura S. 1980a. Thrombin inhibitors. 3. Carboxyl-containing amide derivatives of Nα-substituted L-arginine. J Med Chem 25:1293-1299.
18. Kikumoto R, Tarnao Y, Ohkubo K, Tonomura S. 1980b. Thrombin inhibitors. 2. Amide derivatives of Nα-substituted L-arginine. J Med Chem 23:830-836.
19. Krstenansky JL, Mao SJT. 1987. Antithrombin properties of C-terminus of hirudin using synthetic unsulfated Nα-acetyl-hirudin 45-65. FEBS Lett 211:10-16
20. Lefkovits J, Topol EJ. 1994. Direct thrombin inhibitors in cardiovascular medicine. Circulation 90:1522-1536.
21. Lubin IM, Hayzer DJ, Runge MS. 1992. Strategies for the design of novel thrombolytic and antithrombolytic agents. Trends Cardiovasc Med 2.84-89.
22. Mao SJT, Yates MT, Owen TJ, Krstenansky JL. 1988. Interaction of hirudin with thrombin: Identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry 27:8170-8173.
23. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II. 1990. Design and characterization of hirulogs: A novel class of bivalent inhibitors of thrombin. Biopolymers 29:7095-7101.
24. Marder VJ. 1988. Thrombolytic therapy: Current status. New Engl J Med 318:1512-1520.
25. Markwardt F, Nowak G, Stuerzebecher J, Griessbach U, Walsmann P, Vogel G. 1984. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemostasis 52:160-163.
26. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. 1981. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 101:440-446.
27. Okamoto S, Kinjo K, Hijikata A, Kikumoto R, Tamao Y, Ohkubo K, Tonomura S. 1980. Thrombin inhibitors. I. Ester derivatives of Nα(arylsulfonyl)-L-arginine. J Med Chem 23:827-830.
28. Qiu X, Padmanabhan KP, Carperos VE, Tulinsky A, Kline T, Maraganore JM, Fenton JW II. 1992. Structure of the hirulog 3-thrombin complex and nature of the S′ subsites of substrates and inhibitors. Biochemistry 31:11689-11697.
29. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW II. 1990. The structure of a complex of recombinant hirudin and human α-thrombin. Science 249:277-280.
30. Rydel TJ, Tulinsky A. 1991. Refined structure of the hirudin-thrombin complex. J Mol Biol 221:583-601.
31. Sawyer RT. 1991. Thrombolytics and anticoagulants from leeches. Bio/Technology 9:513-518.
32. Singh J, Thornton JM, Snarey M, Campbell SF. 1987. The geometries of interacting arginine-carboxyls in proteins. FEBS Lett 224:161-71.
33. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A. 1991. Structure of the hirugen and hirulog 1 complexes of α-thrombin. J Mol Biol 221:1379-1393.
34. Stone SR 1995. Thrombin inhibitors. A new generation of antithrombotics. Trends Cardiovasc Med 4:134-140.
35. Stone SR, Hofsteenge J. 1986. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 25:4622-4628.
36. Szewczuk Z, Gibbs BF, Yue SY, Purisima E, Zdanov A, Cygler M. Konishi Y. 1993. Design of a linker for trivalent thrombin inhibitors: Interaction of the main chain of the linker with thrombin. Biochemistry 32:3396-3404.
37. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. 1993. Synthetic low molecular weight thrombin inhibitors: Molecular design and pharmacological profile. Trends Pharmacol Sci 14:366-117.
38. Tsuda Y, Cygler M, Gibbs BF, Pedyczak A, Féthière J, Yue SY, Konishi Y. 1994. Design of potent bivalent thrombin inhibitors based on hirudin sequence: Incorporation of non-substrate type active site inhibitors. Biochemistry 33:14443-14451.
39. Verstraete M. 1990. Thrombolytic treatment in acute myocardial infarction. Circulation 82:II96-II109.
40. Verstraete M. 1993. Les promesses des antithrombotiques. La Recherche 24:606-610.
41. Verstraete M, Zoldhelyi P. 1995. Novel antithrombotic drugs in development. Drugs 49:856-884.
42. Weber PC, Lee SL, Lewandowski FA, Schadt MC, Chang CH, Kettner CA. 1995. Kinetic and crystallographic studies of thrombin with Ac-(D)Phe-Pro-boroArg-OH and its lysine, amidine, homolysine and ornithine analogs. Biochemistry 34.3750-3757.
43. Zdanov A, Wu S, DiMaio J, Konishi Y, Li Y, Wu X, Edwards BFP, Martin PD, Cygler M. 1993 Crystal structure of the complex of human α-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6. Proteins Struct Funct Genet 17:252-265.